Life Sciences Report June 2020 – Clinical

While the Pharmaceutical industry has proven to be more resilient against the impact of the COVID-19 crisis than others, it has not been immune. Indeed, the most immediate impact seems to have been on the Clinical function, where the impact on activity has been striking. Looking at charity-funded studies, the Association of Medical Research Charity essays that most of the clinical trials of their members have had to be stopped, paused or delayed as a result of COVID-19, where many are at risk of not being able to be restarted. AMRC estimates 126,000 patients are affected.